Time: 14:15 GMT

Can dry granulation be a full alternative to wet granulation and also help in developing difficult substances?

Atacama Labs offers fast galenic development and full scale production services to pharmaceutical companies based on an innovative dry granulation technology called PDG (pneumatic dry granulation).

The webinar will lead you through the technology, individual technological and commercial advantages as well as its application fields and show detailed results of a number of APIs developed with the technology.

The advantages and solutions provided are adapted to an audience of galenic developers, production heads and life cycle managers working in the field of Rx/OTC/Generic pharmaceuticals and include a stepwise business model for easy client access and testing.

Attendees to this webinar will understand how this innovative technology can:

•Effectively replace wet granulation with dry granulation with much lower costs and no scale-up issues

•Deliver both flowable and compactable granules

•Solve NCE development issues regarding drug loading, solubility, heat lability, hygrophilic / stability

•Provide effective solutions for ODT forms as well as fixcombinations
This session is followed by a live Q&A with your hosts! Submit your question via the registration form today.

The speakers:
Steffen Mittwich is the CEO of Atacama Labs. Steffen has worked in the pharma industry since 1992 and has held several management positions within major European and international pharmaceutical companies, such as Sanofi-Aventis, Aventis Pharma, and Pfizer. His latest position at Sanofi-Aventis was Regional Business Director and CEO Winthrop Pharmaceuticals. Steffen Mittwich is Industrial Economics Engineer from the Technical University of Karlsruhe, Germany.

Dr. Rob Lammens is the CTO of Atacama Labs. Dr. Robert Lammens is an experienced and acknowledged expert in the Pharmaceutical Technology, especially in dry granulation. He worked at Bayer AG in Leverkusen for 23 years, mainly in the field of solid dosage forms. In addition to his new position as the CTO of Atacama Labs, he will continue as Senior Lecturer at the Department of Pharmaceutical Technology of University of Bonn, where he is coaching several Ph.D. projects in the field of granulation and